Lupin Limited · NSE:LUPIN
Lupin — Q4 FY23 Earnings Presentation
18 slides from Lupin's earnings presentation, May 10, 2023
Slide 1: Exchange filing cover letter
May 10, 2023 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Dear Sir/Madam, Sub: Investor Presentation Q4 FY23 Pursuant to Regulation 30(2) re
Slide 2: Investor Presentation Q4 FY23
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Lupin at a Glance
Lupin at a Glance 3
Slide 5: Lupin Today
Lupin Today Operating from a Position of Strength Global Presence Local Leadership Geographically Diverse (FY23 Sales) 12th Largest in India Pharma Largest Generic 3 rd the US 6th Market Rank 37% INDIA 8% Developed Company (by prescriptions3) Markets (by sales3) (by sales1) 32% Largest South Africa
Slide 6: Vision
Vision A Pharmaceutical Company Focused on Delivering High Quality Medicines to Patients Around the World Global Other United Developed India Region Emerging API States Markets Markets Evolving portfolio and Global operational Delivering innovative pipeline in Complex Global reach and scale efficien
Slide 7: Q4 FY23 Performance
Q4 FY23 Performance 6
Slide 8: Q4 FY23 Key Highlights
Q4 FY23 Key Highlights Continued focus on profitable growth Key Metrics Business Performance INR in mn India North America 43,303 mn 14,786 mn 15,503 mn Revenue 9% YoY 3% QoQ 9% YoY 2% QoQ 12% YoY 2% QoQ 6,150 mn 14% Growth Markets EMEA EBITDA Margin 4,385 mn 4,535 mn 15% YoY 5% QoQ 11% YoY 19% QoQ
Slide 9: Q4 FY23 Financial Snapshot
Q4 FY23 Financial Snapshot Sales Mix Key Financials INR in mn Revenue (In INR mn and %) Q4 FY23 Q3 FY23 Q4 FY22 India, North 14,786, America, 34% Total 15,503, Sales 43,303 42,446 38,645 36% 43,303 EBITDA 6,150 5,506 2,823 API, Growth 3,226, Markets, 7% ROW, EMEA, 4,385, 869, 2% 4,535, 10% PBT 2,585
Slide 10: India: An ongoing story of sustained outperformance
India: An ongoing story of sustained outperformance Lupin has grown better than the market ex-in-licensed Leveraging leadership by adding 6 portfolio across FY23 new divisions Overall Non-IL 14.3% #2 rank #3 rank #3 rank 10.2% 11.3% Respiratory Diabetes Care Cardiac 6.2% 7.6% 7.5% 2.8% Leveraging th
Slide 11: North America: Investing to increase complex share
North America: Investing to increase complex share Leadership: Delivering ~5.5% New product sales driving US Growing Respiratory TRx Gx volume of the U.S.1 growth ($ mn) portfolio US quarterly sales ($ mn) 177 #3 #1 121 159 175 20.5% 48.0% Albuterol market Arfometerol in the US1 in 41 products2 shar
Slide 12: Other Markets: Key Highlights
Other Markets: Key Highlights Other Key Markets driving growth Emerging Markets: Steady growth • Successful MHRA inspection of • BRL 75 mn sales in Q4 FY23 Pithampur facilities (growth 24% LCL YoY); EU Brazil • Acquired Medisol in France – • In reference market, ranks 10th unique hospital business p
Slide 13: Key Financial Metrics: FY23 Quarterly Trend
Key Financial Metrics: FY23 Quarterly Trend R&D (INR mn) Capex (INR Mn) Net debt/ Equity 3,900 15.0% 1,800 7.0% 3,600 3,478 3,376 1,613 13.0% 1,540 1,555 1,502 3,300 3,050 6.0% 0.27 2,896 1,500 0.25 3,000 11.0% 2,700 5.0% 0.21 9.0% 1,200 0.20 2,400 9.6% 2,100 8.3% 4.5% 4.0% 7.0% 900 1,800 6.8% 7.0%
Slide 14: P&L Highlights- Q4 FY23
P&L Highlights- Q4 FY23 QoQ YoY Amount in INR mn Q4FY23 % of Sales Q3FY23 % of Sales Q4FY22 % of Sales Growth Growth Sales 43,303 100.0% 42,446 100.0% 2.0% 38,645 100.0% 12.1% Other operating income 998 2.3% 776 1.8% 28.6% 185 0.5% 439.5% Total revenue 44,301 102.3% 43,222 101.8% 2.5% 38,830 100.5%
Slide 15: P&L Highlights- FY23
P&L Highlights- FY23 YoY Amount in INR mn FY2023 % of Sales FY2022 % of Sales Growth Sales 162,700 100.0% 161,928 100.0% 0.5% Other operating income 3,717 2.3% 2,127 1.3% 74.8% Total revenue 166,417 102.3% 164,055 101.3% 1.4% Gross Profit 94,902 58.3% 97,116 60.0% -2.3% (excl. other operating income
Slide 16: ESG: FY23 Updates and Future Initiatives
ESG: FY23 Updates and Future Initiatives Our Commitment to Responsible Business Practices, Sustainability, Environmental Stewardship and Proactive Risk Management Environment Enhancing targets and tracking for ESG • Adding 22+ MW in FY24 renewable capacity To enhance and take additional targets in t
Slide 17: Lupin – Awards and Accolades
Lupin – Awards and Accolades Organizational Awards Leadership and Other Awards • ATD (Association of Talent Development) • Vinita Gupta, named among India’s 20 Most Influential Women in BEST Award Healthcare by 2022 BW Healthcare World • ‘Factories of the Future’ at the • Goa and Nagpur awarded Gold
Slide 18: Thank you
Thank you REGISTERED OFFICE youtube.com/c/LupinGlobal twitter.com/LupinGlobal 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai – 400 055. India, linkedin.com/company/lupin/ Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051 | www.lupin.com facebook.com/LupinWorld/